Clinical Trial Update: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Ongoing Phase 2 trial evaluating nivolumab in combination with DA-REPOCH chemotherapy for aggressive B-cell non-Hodgkin lymphomas, including primary mediastinal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• Indolent Non-hodgkin Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Non-hodgkin Lymphoma

Drugs mentioned

• Adriamycin (doxorubicin)
• Cytoxan (cyclophosphamide)
• Deltasone (prednisone)
• OPDIVO (nivolumab)
• Oncovin (vincristine)
• Rituxan (rituximab)
• VePesid (etoposide)

Snippet

Sponsor: David Bond, MD | Conditions: Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING